MA39711A - Conjugués d'une fraction d'il-15 et d'un polymère - Google Patents

Conjugués d'une fraction d'il-15 et d'un polymère

Info

Publication number
MA39711A
MA39711A MA039711A MA39711A MA39711A MA 39711 A MA39711 A MA 39711A MA 039711 A MA039711 A MA 039711A MA 39711 A MA39711 A MA 39711A MA 39711 A MA39711 A MA 39711A
Authority
MA
Morocco
Prior art keywords
conjugates
moiety
polymer
nonpeptidic
methods
Prior art date
Application number
MA039711A
Other languages
English (en)
Inventor
Thomas Chang
Deborah H Charych
Peter Benedict Kirk
Xiaofeng Liu
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of MA39711A publication Critical patent/MA39711A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C08G65/48—Polymers modified by chemical after-treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des conjugués d'une fraction d'il-11 et d'un ou de plusieurs polymères non peptidiques, solubles dans l'eau. Typiquement, le polymère non peptidique, soluble dans l'eau est un poly(éthylène glycol) ou un dérivé de celui-ci. L'invention porte également, entre autres, sur des compositions comprenant des conjugués, des procédés de fabrication de conjugués et des procédés d'administration de compositions à un individu.
MA039711A 2014-04-03 2015-03-31 Conjugués d'une fraction d'il-15 et d'un polymère MA39711A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461974914P 2014-04-03 2014-04-03

Publications (1)

Publication Number Publication Date
MA39711A true MA39711A (fr) 2015-10-08

Family

ID=54241432

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039711A MA39711A (fr) 2014-04-03 2015-03-31 Conjugués d'une fraction d'il-15 et d'un polymère

Country Status (12)

Country Link
US (1) US20170035898A1 (fr)
EP (2) EP3919071A1 (fr)
JP (2) JP6728055B2 (fr)
KR (1) KR102432169B1 (fr)
CN (1) CN106456716A (fr)
AU (3) AU2015240806B2 (fr)
CA (1) CA2942571C (fr)
ES (1) ES2876433T3 (fr)
IL (1) IL248169A0 (fr)
MA (1) MA39711A (fr)
MX (2) MX388865B (fr)
WO (1) WO2015153753A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2986306A4 (fr) 2013-04-18 2016-12-07 Armo Biosciences Inc Méthodes d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
CA2914837A1 (fr) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Methode d'evaluation de l'identite et de la stabilite d'une proteine
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
KR20160079114A (ko) 2013-11-11 2016-07-05 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
WO2015187295A2 (fr) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Méthodes permettant de faire baisser le cholestérol sérique
EP3206713A4 (fr) 2014-10-14 2018-06-27 Armo Biosciences, Inc. Compositions d'interleukine-15 et leurs utilisations
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
WO2016191587A1 (fr) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Interleukine 10 pégylée utilisée pour le traitement du cancer
CA2995120A1 (fr) 2015-08-25 2017-03-02 Armo Biosciences, Inc. Procedes d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
WO2017062832A1 (fr) 2015-10-08 2017-04-13 Nektar Therapeutics Combinaison d'un agoniste sélectif de l'il-2rbeta et d'un agoniste de l'il-15 à action prolongée
MX2018007304A (es) * 2015-12-21 2019-03-14 Armo Biosciences Inc Composiciones de interleucina-15 y sus usos.
CN109715196A (zh) 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
KR20250057110A (ko) * 2017-05-15 2025-04-28 넥타르 테라퓨틱스 지속 작용성 인터류킨-15 수용체 효현제 및 관련 면역요법 조성물 및 방법
CA3074826A1 (fr) 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Compositions proteiques therapeutiques et procedes de preparation et d'utilisation de celles-ci
AU2019224159B2 (en) * 2018-02-26 2025-05-29 Sanofi IL-15 conjugates and uses thereof
JP7611136B2 (ja) * 2018-11-09 2025-01-09 ネクター セラピューティクス 別の薬理学的に活性な薬剤と組み合わせた長時間作用型インターロイキン－１５受容体作動薬
WO2020219943A1 (fr) * 2019-04-26 2020-10-29 Prolynx Llc Conjugués de cytokine à libération lente
WO2020247388A2 (fr) 2019-06-03 2020-12-10 Medikine, Inc. Composés de liaison de sous-unité de récepteur il-2alpha
CA3148135A1 (fr) * 2019-08-23 2021-03-04 Carolina E. CAFFARO Conjugues d'il-15 et leurs utilisations
KR20240004403A (ko) * 2021-03-29 2024-01-11 오디 쎄라퓨틱스 리미티드 단백질-거대분자 접합체 및 이의 사용 방법
JP2024526080A (ja) 2021-06-23 2024-07-17 サイチューン ファーマ インターロイキン１５多様体
US20250270273A1 (en) * 2021-07-12 2025-08-28 Nektar Therapeutics Polymer engineered forms of interferon-gamma and methods of use
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (fr) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Polythérapies d'agoniste de récepteur de cytokine et de vecteur viral
WO2025101551A1 (fr) * 2023-11-06 2025-05-15 Regents Of The University Of Minnesota Peptides de liaison à l'antigène membranaire spécifique de la prostate (psma) et procédé d'utilisation

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US6110721A (en) * 1993-11-12 2000-08-29 Gilead Sciences, Inc. Polypeptides and coagulation therapy
WO1995027722A1 (fr) 1994-04-06 1995-10-19 Immunex Corporation Interleukine-15
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US7008624B1 (en) * 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
CA2323048C (fr) 1998-03-12 2006-10-10 Shearwater Polymers, Inc. Derives de poly(ethylene glycol) avec groupes reactifs proximaux
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
ATE444984T1 (de) * 2002-12-31 2009-10-15 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
US7910661B2 (en) 2003-01-06 2011-03-22 Nektar Therapeutics Thiol-selective water-soluble polymer derivatives
US7276478B2 (en) * 2003-09-25 2007-10-02 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
US20060057680A1 (en) * 2004-08-11 2006-03-16 Zheng Xin X Mutant interleukin-15 polypeptides
US20060104945A1 (en) 2004-10-05 2006-05-18 Choi Yong S Enhancement of B cell proliferation by IL-15
US20060257361A1 (en) * 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
CA2611823C (fr) 2005-06-16 2013-07-30 Nektar Therapeutics Al, Corporation Conjugues a liaison degradable et reactifs polymeres utilises dans la preparation de ces conjugues
CN106046370A (zh) 2007-02-28 2016-10-26 塞瑞纳治疗公司 聚噁唑啉poz化合物、合成其的方法、以及靶分子‑poz偶联物
JP5775820B2 (ja) * 2008-10-21 2015-09-09 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 遊離可能ｐｅｇ試薬を有するプロドラッグｐｅｇタンパク質結合体において活性成分（インビトロ脱ペグ化）を決定する方法
TWI534152B (zh) * 2010-07-30 2016-05-21 巴克斯特國際公司 用於肟連接的親核性催化劑
ES2866674T3 (es) * 2010-11-12 2021-10-19 Nektar Therapeutics Conjugados de una fracción de IL-2 y un polímero
CN102145178B (zh) * 2011-04-15 2012-09-26 北京凯因科技股份有限公司 Peg化白介素15
WO2013020079A2 (fr) * 2011-08-04 2013-02-07 Nektar Therapeutics Conjugués d'une fraction il-11 et d'un polymère

Also Published As

Publication number Publication date
AU2019283778A1 (en) 2020-01-16
AU2015240806B2 (en) 2019-09-19
MX2021015492A (es) 2022-02-22
CN106456716A (zh) 2017-02-22
KR20170005793A (ko) 2017-01-16
JP2020114875A (ja) 2020-07-30
EP3139947A2 (fr) 2017-03-15
WO2015153753A3 (fr) 2015-11-26
JP6728055B2 (ja) 2020-07-22
EP3139947B8 (fr) 2021-06-30
AU2015240806A1 (en) 2016-10-13
EP3139947B1 (fr) 2021-05-26
CA2942571A1 (fr) 2015-10-08
ES2876433T3 (es) 2021-11-12
KR102432169B1 (ko) 2022-08-11
EP3919071A1 (fr) 2021-12-08
MX2016012908A (es) 2017-01-11
IL248169A0 (en) 2016-11-30
AU2021258008A1 (en) 2021-11-25
MX388865B (es) 2025-03-20
EP3139947A4 (fr) 2018-01-17
WO2015153753A2 (fr) 2015-10-08
JP2017511322A (ja) 2017-04-20
CA2942571C (fr) 2023-09-19
US20170035898A1 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
MX2021015492A (es) Conjugados de un resto de interleucina-15 (il-15) y un polimero.
MX2017011562A (es) Conjugados de un resto de il-7 y un polimero.
MX382791B (es) Conjugados novedosos de glicano y uso de los mismos
SG10201909805XA (en) Surface modified polymer compositions
MX2016009943A (es) Composiciones de nanotribologia y metodos relacionados que incluyen nanolaminas moleculares.
MX381160B (es) Agonistas del receptor de apelina y metodos de uso.
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
MX2013005363A (es) Conjugados de un resto de interleucina-2 y un polimero.
EP3037475A4 (fr) Ester actif de phénoxycyclotriphosphazène, composition de résine sans halogènes et son utilisation
EP4252681A3 (fr) Objets implantables, dispositifs de guidage, et procédés d'utilisation
WO2016022943A3 (fr) Nouveaux monomères dérivés de biomasse
MX2013007230A (es) Sistemas de polimero.
WO2015035342A3 (fr) Conjugués polymère zwittérionique-facteur viii
WO2013020079A3 (fr) Conjugués d'une fraction il-11 et d'un polymère
ZA201803476B (en) Anti-cd22 antibody-maytansine conjugates and methods of use thereof
EP3510117A4 (fr) Compositions de lignine glyoxalée
MY181478A (en) Mixed decyl mercaptans compositions and methods of making same
MX385886B (es) Macromoleculas estrellas compatibles con tensoactivos.
MY191782A (en) A process to prepare a polyester polymer and a polyester polymer obtainable thereby
EP3478663A4 (fr) Polymère fonctionnalisé par un lactame, compositions et applications de celui-ci
MX2018005085A (es) Nanoparticulas terapeuticas que comprenden un agente terapeutico y metodos de fabricacion y uso de las mismas.
IL259891A (en) Organic solvent free compositions comprising protein-polymer conjugates and uses thereof
TW201614007A (en) Composition for forming silica layer, silica layer, and electronic device
EP3137517A4 (fr) Copolymère à faible teneur en oligomère cyclique
MX2020002908A (es) Composicion acuosa de polimeros.